Following the FDA 's rejection of Qnexa and lorcaserin, Orexigen (OREX) makes it three for...

|About: Orexigen Therapeut... (OREX)|By:, SA News Editor

Following the FDA 's rejection of Qnexa and lorcaserin, Orexigen (OREX) makes it three for three, as the FDA issues a Complete Response Letter for Contrave, saying it wants another trial to rule out cardiovascular risk. After a halt, shares are down almost 70% premarket.